Sands, B. E., Irving, P. M., Hoops, T., Izanec, J. L., Gao, L.-L., Gasink, C., … Zdena, Z. (2022). Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. The Lancet, 399(10342), 2200–2211. https://doi.org/10.1016/s0140-6736(22)00688-2

Sands, Bruce E., Peter M. Irving, Timothy Hoops, James L. Izanec, Long-Long Gao, Christopher Gasink, Andrew Greenspan, et al. “Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.” The Lancet 399, no. 10342 (June 2022): 2200–2211. https://doi.org/10.1016/s0140-6736(22)00688-2.

Sands BE, Irving PM, Hoops T, Izanec JL, Gao L-L, Gasink C, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. The Lancet. 2022 Jun;399(10342):2200–11.

Sands, Bruce E., et al. “Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.” The Lancet, vol. 399, no. 10342, Elsevier BV, June 2022, pp. 2200–11. Crossref, doi:10.1016/s0140-6736(22)00688-2.

Sands BE, Irving PM, Hoops T, Izanec JL, Gao L-L, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ, Afzali A, Aitova L, Aldeguer i Mante X, Altorjay I, Argüelles Arias F, Armuzzi A, Augustyn M, Bafutto M, Barrio J, Begun J, Behrend C, Bezemer G, Bonnaud G, Brankovic M, Byung IJ, Calvet Calvo X, Chachu K, Chebli JMF, Cheon JH, Cichoz-Lach H, Clark L, Cummings F, Dalal K, De Boer N, De Lourdes Ferrari M, Désilets E, Dugalic P, Duvall G, Fedorishina O, Filip R, Flores C, Fogel R, Fon J, Frankel M, Friedenberg K, Fries W, Galina V, Gietka P, Goel R, Hasselblatt P, Herfarth H, Herszényi L, Hindryckx P, Hoentjen F, Horjus Talabur Horje C, Iduru S, Irving P, Isfort R, Jones M, Kalimullina D, Katz J, Kaur M, Khurana SK, Kim JS, Kim Y, Kleczkowski D, Knezevic S, Knoll A, Korman LY, Kotzev I, Kulyapin A, Lee KM, Leemreis D, Leszczyszyn J, Limdi J, Lissauer J, Loftus E, Malecka-Panas E, Marshall J, Mihály E, Milan L, Monteleone G, Nagorni A, Owczarek D, Palekar N, Park YS, Park SH, Parra R, Patai Á, Patel K, Patel B, Pershko A, Petrova E, Pineton de Chambrun G, Randall C, Riestra Menendez S, Ritter T, Rivero M, Roblin X, Rocca R, Romatowski J, Rydzewska G, Saibeni S, Salzberg B, Sarles H, Saunders J, Savarino EV, Serclova Z, Shchukina O, Siegel J, Soofi N, Sparrow M, Stokesberry D, Suiter D, Svorcan P, Tkachev A, Tsonev N, Tünde K, Ulbrych J, Vanasek T, Varga M, Vermeire S, Vicente Lidon R, Weiss ML, Wesley E, Winstead N, Wojcik K, Wypych J, Zaltman C, Zdena Z. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. The Lancet. Elsevier BV; 2022 Jun;399(10342):2200–2211.